Report
Luis Arredondo
EUR 50.00 For Business Accounts Only

GRIFOLS: POSITIVE MESSAGES FROM CONFERENCE CALL ON BIOTEST AG ACQUISITION (ANÁLISIS BANCO SABADELL)

Highlights from the conference call on the Biotest AG acquisition:
 2024/26 Synergies & estimates: The € 300 M of incremental EBITDA GRF expects Biotest to generate in 2024 is broken down into: € 104 M EBITDA from the recurring business, € 65 M from Opex synergies (mainly backoffice duplicities) and € 138 M from the contribution derived from the launch of 2 new plasma proteins in the pipeline (IgM and Fibrinogen).
Underlying
Provider
Sabadell
Sabadell

Analysts
Luis Arredondo

Other Reports on these Companies
Other Reports from Sabadell

ResearchPool Subscriptions

Get the most out of your insights

Get in touch